Group 1 - Several A-share listed companies are facing delisting risks due to suspected financial fraud or information disclosure violations, with *ST Zitian, *ST Suwu, *ST Tianmao, and *ST Gaohong being the focus of investor attention [1] - *ST Gaohong has been subjected to mandatory delisting procedures by the Shenzhen Stock Exchange due to serious financial fraud and has incurred an administrative fine of 160 million yuan [1] - *ST Tianmao announced its intention to voluntarily withdraw its A-shares from trading on the Shenzhen Stock Exchange through a shareholders' meeting resolution [1] Group 2 - A total of 23 companies have been delisted from the A-share market this year, primarily due to financial-related delisting, trading-related delisting, major illegal mandatory delisting, and voluntary delisting [2] - Companies such as Zhonghang Chanyin and Yulong Co. are categorized as voluntary delisting, while companies like Tuishe Zhuolang and Tuishe Jinguang are classified under major illegal mandatory delisting [2] - Several companies, including *ST Furun, *ST Dongfang, *ST Xulan, *ST Jiayu, and *ST Jiyuan, have been delisted due to stock prices falling below par value [2]

| 股票名称 | 监控开始日期 监控结束日期 异动开始日期 | | | --- | --- | --- | | 东芯股份 | 2025-08-08 2025-08-21 | 2025-07-25 | | 688110 | | | | 北方长龙 | 2025-08-08 2025-08-21 | 2025-07-28 | | 301357 | | | | 东杰智能 | 2025-08-05 2025-08-18 未披露 | | | 300486 | | | | 南方路机 | 2025-08-01 2025-08-14 未披露 | | | 603280 | | | | 西藏旅游 | 2025-07-31 2025-08-13 2025-07-21 | | | 600749 | | | | 上纬新材 | 2025-07-31 2025-08-13 未披露 | | | ୧୫୫୧୫୧ | | | | 幸福蓝海 | 2025-07-31 2025-08-13 | 2025-07-24 | | 300528 | | | 根据交易所规则,股票交易出现严重异常波动情形后10个交易 日内. 连续竞价阶段1分钟内单向申报买入(卖出 ...

New Stock Listings - Tianfu Long (603406) issued at a price of 23.60[1] - Youli Intelligent (920007) issued at a price of 23.99[1] Rights Issues and Announcements - China Heavy Industry (601989) cash option declaration period from August 13, 2025[1] - China Shipbuilding (600150) acquisition request period from August 13 to August 15, 2025[1] - Shenkai Co., Ltd. (002633) offer declaration period from July 29 to August 27, 2025[1] - ST Kelly (300326) offer period from July 17 to August 15, 2025[1] - Fushun Special Steel (600399) offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - Multiple stocks reported abnormal fluctuations, including *ST Yushun (002289) and Changcheng Military Industry (601606)[2][3] - Notable fluctuations also reported for companies like Li De Man (300289) and Dongjie Intelligent (300486)[3]

Core Viewpoint - The dispute over the exclusive agency rights for the "童颜针" (AestheFill) between *ST Suwu and Aimeike highlights the lucrative nature of the medical beauty industry, particularly the significant revenue generated by AestheFill for *ST Suwu, which could be jeopardized by the termination of the agency agreement [1][2][8]. Group 1: Agency Dispute - Aimeike announced the termination of the exclusive distribution agreement for AestheFill, which affects *ST Suwu's subsidiary, Datuo Medical, potentially leading to a loss of significant revenue [2][3]. - The reasons for the termination include alleged violations of the agreement by Datuo Medical and serious legal issues faced by *ST Suwu's executives, which have impacted the reputation of AestheFill in China [3][5]. - *ST Suwu refuted these claims, asserting that there was no transfer of agency rights and that the termination was unjustified, indicating potential legal actions against Aimeike [5][6]. Group 2: Financial Impact - AestheFill contributed over 3 billion yuan in revenue to *ST Suwu within a year, representing a 4000% increase in the medical beauty segment's performance [1][8]. - If the agency agreement is terminated, *ST Suwu anticipates a significant decline in revenue and profit from its medical beauty segment, with AestheFill projected to account for 20.42% of total revenue in 2024 [8][11]. - Aimeike's corresponding product, "濡白天使," has also shown strong performance, with revenues increasing from 385 million yuan in 2021 to 1.216 billion yuan in 2024, indicating robust growth in the medical beauty market [13]. Group 3: Market Dynamics - The medical beauty injection market, particularly for products like AestheFill, is expected to grow rapidly, with projections estimating a market size of 11.52 billion yuan by 2027 and a compound annual growth rate of 54.73% from 2021 to 2025 [9]. - The competition in the "童颜针" market is intensifying, with multiple players entering the space, including products from Aimeike, Korean REGEN, and others, indicating a crowded and competitive landscape [15].

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-081 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第五次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 2、根据《上海证券交易所股票上市规则》第 9.5.7 条、第 9.5.8 条，如公 司后续收到行政处罚决定书，显示公司触及重大违法类强制退市情形，公司将申 请停牌，并及时披露有关内容。上海证券交易所将在停牌之日起的 5 个交易日内， 向公司发出拟终止股票上市的事先告知书，后续将根据《上海证券交易所股票上 市规则》的相关规定，作出是否终止公司股票上市的决定。 公司指定信息披露媒体为《中国证券报》《上海证券报》以及上海证券交易 所网站（www.sse.com.cn），有关公司的信息均以上述指定媒体刊登的信息为准。 敬请投资者注意投资风险。 特此公告。 江苏吴中医药发展股份有限公司(以下简称"公司")因涉嫌信息披露违 法违规，被中国证券监督管理委员会（以下简称"中国证监会"）立案 调查。2025 年 7 月 ...

根据交易所规则,股票交易出现严重异常波动情形后10个交易 日内,连续竞价阶段1分钟内单向申报买入(卖出)单只严重异常 波动股票金额巨大的,交易所对有关交易行为予以重点监控。 异动监控股票 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 | 股票名称 | 监控开始日期 监控结束日期 异动开始日期 | | --- | --- | | 东杰智能 | 2025-08-05 2025-08-18 未披露 | | 300486 | | | 南方路机 | 2025-08-01 2025-08-14 未披露 | | 603280 | | | 西藏旅游 | 2025-07-31 2025-08-13 2025-07-21 | | 600749 | | | 上纬新材 | 2025-07-31 2025-08-13 未披露 | | 688585 | | | 幸福蓝海 | 2025-07-31 2025-08-13 2025-07-24 | | 300528 | | | *ST苏吴 | 2025-07-30 2025-08-12 未披露 | | 600200 | | | 横河精密 | 2025-07 ...

按最新收盘价计算，A股均价为12.49元，不足2元的个股共有37只，股价最低的是*ST苏吴，最新收盘 价为1.08元。 证券时报·数据宝统计显示，截至8月6日收盘，沪指报收3633.99点，A股平均股价为12.49元，从个股股 价分布看，高价股及低价股数量在A股市场总体占比相对较少。 低价股中，股价低于2元的共有37只，最低的是*ST苏吴，最新收盘价为1.08元，其次是*ST金科、荣盛 发展，最新收盘价分别为1.41元、1.41元。特征来看，股价低于2元个股中，共有12只ST股上榜，占比 为32.43%。 | 代码 | 简称 | 最新收盘价（元） | 日涨跌幅（%） | 日换手率（%） | 市净率（倍） | 行业 | | --- | --- | --- | --- | --- | --- | --- | | 600200 | *ST苏吴 | 1.08 | -4.42 | 15.26 | 0.44 | 医药生物 | | 000656 | *ST金科 | 1.41 | 0.00 | 1.02 | | 房地产 | | 002146 | 荣盛发展 | 1.41 | -0.70 | 1.60 | 0.44 | 房地产 ...

*免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 | 股票名称 | 监控开始日期 监控结束日期 异动开始日期 | | --- | --- | | 南方路机 | 2025-08-01 2025-08-14 未披露 | | 603280 | | | 西藏旅游 | 2025-07-31 2025-08-13 2025-07-21 | | 600749 | | | 上纬新材 | 2025-07-31 2025-08-13 未披露 | | 688585 | | | 幸福蓝海 | 2025-07-31 2025-08-13 2025-07-24 | | 300528 | | | *ST苏吴 | 2025-07-30 2025-08-12 未披露 | | 600200 | | | 横河精密 | 2025-07-30 2025-08-12 2025-07-21 | | 300539 | | | 上纬新材 | 2025-07-29 2025-08-11 未披露 | | 688585 | | | 上纬新材 | 2025-07-28 2025-08-08 未披露 | | 688585 | | 根据交 ...

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. has experienced significant stock price fluctuations, with a cumulative decline exceeding 12% over three consecutive trading days, leading to abnormal trading conditions [4]. Group 1: Stock Trading Abnormalities - The company's stock price fell by more than 12% cumulatively over three trading days (August 1, August 4, and August 5, 2025), indicating abnormal trading conditions [4]. - The company has received a notice from the China Securities Regulatory Commission (CSRC) regarding administrative penalties due to inflated revenue and profit figures in its annual reports from 2020 to 2023 [10]. Group 2: Financial Reporting Issues - The company's 2024 annual financial report received a disclaimer of opinion from the auditing firm, which may lead to delisting risks under the Shanghai Stock Exchange rules [2][3]. - There are issues related to non-operating fund occupation by related parties of the controlling shareholder, with a reported balance of 169.26 million yuan as of the end of 2023 [11]. Group 3: Operational Status - The company has confirmed that, aside from disclosed matters, there have been no significant changes in its daily operations or external environment [5]. - No undisclosed major events, such as asset restructuring or significant business cooperation, have been identified [6]. Group 4: Risks and Future Considerations - The company is under a delisting risk warning due to the CSRC's findings, which could lead to mandatory delisting if further penalties are imposed [10]. - The company’s subsidiary may lose exclusive rights to sell a product, which could significantly impact revenue and profits in the second half of the year [12].

证券代码：600200 证券简称：*ST苏吴 公告编号：临2025-080 江苏吴中医药发展股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、公司关注并核实的相关情况 （一）生产经营情况 经自查，除公司已披露的事项外，截至本公告披露日，公司日常生产经营及 外部环境未发生其他重大变化。 （二）重大事项情况 重要风险提示： ? 江苏吴中医药发展股份有限公司（以下简称"公司"）股票连续三个交 易日内收盘价格跌幅偏离值累计超过 12%，属于股票交易异常波动的情形。 ? 2025 年 7 月 13 日，公司收到中国证券监督管理委员会（以下简称"中 国证监会"）下发的《行政处罚事先告知书》（处罚字〔2025〕58 号），具体 内容详见公司于 2025 年 7 月 14 日披露的《关于收到中国证券监督管理委员会< 行政处罚事先告知书>的公告》（公告编号：临 2025-064）。公司股票已于 2025 年 7 月 14 日起被叠加实施退市风险警示，如根据中国证监会正式的处罚决定书 结论，公司触及重大违法 ...